Investors Buy Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw some unusual options trading activity on Friday. Investors acquired 22,003 call options on the company. This represents an increase of approximately 239% compared to the typical volume of 6,490 call options.

Insider Activity at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,647,966. The trade was a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $6.84, for a total transaction of $78,297.48. Following the completion of the sale, the director now owns 7,109,875 shares of the company’s stock, valued at approximately $48,631,545. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 134,235 shares of company stock worth $895,538 in the last 90 days. 15.75% of the stock is owned by corporate insiders.

Institutional Trading of Recursion Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Axxcess Wealth Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 4.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after acquiring an additional 1,795 shares during the last quarter. Green Alpha Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 2.9% in the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after acquiring an additional 1,800 shares during the last quarter. Interchange Capital Partners LLC boosted its holdings in shares of Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after acquiring an additional 2,349 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after acquiring an additional 2,598 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 21.5 %

NASDAQ:RXRX opened at $8.01 on Friday. The company has a market cap of $2.30 billion, a PE ratio of -5.24 and a beta of 0.85. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $15.74. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average is $6.61 and its two-hundred day moving average is $7.34.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s revenue for the quarter was up 147.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.43) EPS. Analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Analysts Set New Price Targets

RXRX has been the subject of several recent analyst reports. Leerink Partners reduced their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.